jk07
mAbexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Mar 15, 2020 (NCT04210375)
Timeline
Indications
Mechanism of action
NRG1 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07221513 | Phase 2 | Nov 30, 2025 | Salubris Biotherapeutics Inc |
| NCT06369298 | Phase 2 | Mar 28, 2024 | Salubris Biotherapeutics Inc |
| NCT05322616 | Phase 1 | Oct 21, 2022 | Salubris Biotherapeutics Inc, The Cleveland Clinic |
| NCT04210375 | Phase 1 | Mar 15, 2020 | Salubris Biotherapeutics Inc, The Cleveland Clinic |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Salubris Biotherapeutics Inc | For profit | 4 | 4 | 2 | 2020 |
| The Cleveland Clinic | Academic/Hospital | 2 | 0 | 1 | 2020 |
2 organizations
Page 1 / 1